Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | WEE1 | P30291 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504264 | 0.99 | PTGDR2 (0.41) | PTGDR2TDP1AKR1B10AKR1B1WEE1 | |
| SCHEMBL6505761 | 0.98 | PTGDR2 (0.41) | PTGDR2TDP1AKR1B10AKR1B1WEE1 | |
| SCHEMBL6505755 | 0.88 | TDP1 (0.40) | TDP1WEE1CHEK1ALDH1A1GAA | |
| SCHEMBL6503691 | 0.82 | TDP1 (0.40) | TDP1WEE1CHEK1GAAMAPT | |
| SCHEMBL6495062 | 0.81 | WEE1 (0.50) | TDP1WEE1CHEK1 | |
| SCHEMBL6505681 | 0.80 | NTRK1 (0.43) | TDP1WEE1CHEK1ALDH1A1GAA | |
| SCHEMBL6498347 | 0.78 | TDP1 (0.61) | TDP1WEE1CHEK1 | |
| SCHEMBL6202615 | 0.68 | WEE1 (0.47) | TDP1WEE1CHEK1ALDH1A1 | |
| SCHEMBL6504952 | 0.67 | WEE1 (0.41) | TDP1WEE1ALDH1A1GAAMAPT | |
| SCHEMBL6200718 | 0.67 | L3MBTL1 (0.47) | TDP1ALDH1A1GAAMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844445-B2 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2005-01-18 | — | — | US | disclosed |
| US-20020173531-A1 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173531-A1 | Indenoindolone compounds | MTNR1A, MTNR1B, CYP11B1 | PTGDR2 221/4885TDP1 2566/4885AKR1B10 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.